TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING INVESTMENT IN RESEARCH & DEVELOPMENT
4.2.2 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES
4.3 RESTRAINTS
4.3.1 HIGH COST OF THE MONOCLONAL ANTIBODY SERVICES
4.4 OPPORTUNITIES
4.4.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION
5.1.4 MARKETING AND SALES
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON REGIONS
5.3.4 DEMAND-SUPPLY GAP ANALYSIS
6 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY SOURCE
6.1 OVERVIEW
6.2 RAT/MOUSE CUSTOM MONOCLONAL ANTIBODY
6.3 RABBIT CUSTOM MONOCLONAL ANTIBODY
6.4 CAMELID CUSTOM ANTIBODY
6.5 OTHERS
7 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY TYPE
7.1 OVERVIEW
7.2 PRIMARY ANTIBODIES
7.3 SECONDARY ANTIBODIES
8 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DIAGNOSTIC APPLICATION
8.2.1 BIOCHEMICAL ANALYSIS
8.2.1.1 PREGNANCY
8.2.1.2 CANCER
8.2.1.3 HORMONAL DISORDER
8.2.1.4 INFECTIOUS DISEASE
8.2.2 DIAGNOSTIC IMAGING
8.2.2.1 CARDIOVASCULAR DISEASES
8.2.2.2 CANCER
8.2.2.3 BACTERIAL INFECTIONS
8.2.2.4 OTHERS
8.3 THERAPEUTIC APPLICATION
8.3.1 MAB AS THERAPEUTIC AGENTS
8.3.2 MAB AS TARGETING AGENTS
8.4 RESEARCH APPLICATION
9 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 RESEARCH & ACADEMIC LABORATORIES
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.5 OTHERS
10 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET
11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET
11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.5.1 MERGERS & ACQUISITIONS
11.6 MAJOR PLAYERS SALES ANALYSIS
11.6.1 SALES & OPERATING INCOME
11.6.2 MAJOR PLAYERS R&D ANALYSIS
12 COMPANY PROFILE
12.1 THERMO FISHER SCIENTIFIC INC.
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 GENSCRIPT
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 ABNOVA CORPORATION
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 CREATIVE BIOLABS
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 ABCAM PLC
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 PROMAB BIOTECHNOLOGIES, INC.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 INOTIV. (ENVIGO)
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 SERVICES OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 BIOLEGEND, INC.
12.8.1 COMPANY OVERVIEWS
12.8.2 FINANCIAL OVERVIEW
12.8.3 SERVICES OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 SINO BIOLOGICAL, INC.
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 SERVICES OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 PROTEOGENIX
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY SOURCE, 2022-2030 (USD MILLION)
TABLE 4 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR RAT/MOUSE CUSTOM MONOCLONAL ANTIBODY, BY REGION, 2022-2030 (USD MILLION)
TABLE 5 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR RABBIT CUSTOM MONOCLONAL ANTIBODY, BY REGION, 2022-2030 (USD MILLION)
TABLE 6 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR CAMELID CUSTOM ANTIBODY, BY REGION, 2022-2030 (USD MILLION)
TABLE 7 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION)
TABLE 8 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 9 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR PRIMARY ANTIBODIES, BY REGION, 2022-2030 (USD MILLION)
TABLE 10 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR SECONDARY ANTIBODIES, BY REGION, 2022-2030 (USD MILLION)
TABLE 11 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
TABLE 12 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC APPLICATION, BY REGION, 2022-2030 (USD MILLION)
TABLE 13 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET FOR DIAGNOSTIC APPLICATON, BY TYPE, 2022-2030 (USD MILLION)
TABLE 14 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET FOR BIOCHEMICAL ANALYSIS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 15 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR PREGNANCY, BY REGION, 2022-2030 (USD MILLION)
TABLE 16 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR CANCER, BY REGION, 2022-2030 (USD MILLION)
TABLE 17 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR HORMONAL DISORDER, BY REGION, 2022-2030 (USD MILLION)
TABLE 18 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR INFECTIOUS DISEASE, BY REGION, 2022-2030 (USD MILLION)
TABLE 19 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET FOR DIAGNOSTIC IMAGING, BY TYPE, 2022-2030 (USD MILLION)
TABLE 20 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2030 (USD MILLION)
TABLE 21 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR CANCER, BY REGION, 2022-2030 (USD MILLION)
TABLE 22 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR BACTERIAL INFECTIONS, BY REGION, 2022-2030 (USD MILLION)
TABLE 23 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION)
TABLE 24 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR THERAPEUTIC APPLICATION, BY REGION, 2022-2030 (USD MILLION)
TABLE 25 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET FOR THERAPEUTIC APPLICATON, BY TYPE, 2022-2030 (USD MILLION)
TABLE 26 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR MAB AS THERAPEUTIC AGENTS, BY REGION, 2022-2030 (USD MILLION)
TABLE 27 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR MAB AS TARGETING AGENTS, BY REGION, 2022-2030 (USD MILLION)
TABLE 28 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR RESEARCH APPLICATION, BY REGION, 2022-2030 (USD MILLION)
TABLE 29 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 30 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR HOSPITALS, BY REGION, 2022-2030 (USD MILLION)
TABLE 31 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2022-2030 (USD MILLION)
TABLE 32 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2030 (USD MILLION)
TABLE 33 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION)
TABLE 34 GLOBAL MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY REGION, 2022-2030 (USD MILLION)
TABLE 35 NORTH AMERICA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
TABLE 36 NORTH AMERICA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY SOURCE, 2022-2030 (USD MILLION)
TABLE 37 NORTH AMERICA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 38 NORTH AMERICA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
TABLE 39 NORTH AMERICA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC APPLICATION, BY TYPE, 2022-2030 (USD MILLION)
TABLE 40 NORTH AMERICA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR BIOCHEMICAL ANALYSIS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 41 NORTH AMERICA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC IMAGING, BY TYPE, 2022-2030 (USD MILLION)
TABLE 42 NORTH AMERICA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR THERAPEUTIC APPLICATON, BY TYPE, 2022-2030 (USD MILLION)
TABLE 43 NORTH AMERICA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 44 US: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY SOURCE, 2022-2030 (USD MILLION)
TABLE 45 US: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 46 US: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
TABLE 47 US: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC APPLICATION, BY TYPE, 2022-2030 (USD MILLION)
TABLE 48 US: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR BIOCHEMICAL ANALYSIS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 49 US: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC IMAGING, BY TYPE, 2022-2030 (USD MILLION)
TABLE 50 US: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR THERAPEUTIC APPLICATON, BY TYPE, 2022-2030 (USD MILLION)
TABLE 51 US: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 52 CANADA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY SOURCE, 2022-2030 (USD MILLION)
TABLE 53 CANADA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 54 CANADA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
TABLE 55 CANADA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC APPLICATION, BY TYPE, 2022-2030 (USD MILLION)
TABLE 56 CANADA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR BIOCHEMICAL ANALYSIS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 57 CANADA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC IMAGING, BY TYPE, 2022-2030 (USD MILLION)
TABLE 58 CANADA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR THERAPEUTIC APPLICATON, BY TYPE, 2022-2030 (USD MILLION)
TABLE 59 CANADA: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 60 EUROPE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
TABLE 61 EUROPE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY SOURCE, 2022-2030 (USD MILLION)
TABLE 62 EUROPE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 63 EUROPE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
TABLE 64 EUROPE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC APPLICATION, BY TYPE, 2022-2030 (USD MILLION)
TABLE 65 EUROPE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR BIOCHEMICAL ANALYSIS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 66 EUROPE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC IMAGING, BY TYPE, 2022-2030 (USD MILLION)
TABLE 67 EUROPE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR THERAPEUTIC APPLICATON, BY TYPE, 2022-2030 (USD MILLION)
TABLE 68 EUROPE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 69 GERMANY: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY SOURCE, 2022-2030 (USD MILLION)
TABLE 70 GERMANY: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 71 GERMANY: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
TABLE 72 GERMANY: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC APPLICATION, BY TYPE, 2022-2030 (USD MILLION)
TABLE 73 GERMANY: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR BIOCHEMICAL ANALYSIS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 74 GERMANY: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC IMAGING, BY TYPE, 2022-2030 (USD MILLION)
TABLE 75 GERMANY: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR THERAPEUTIC APPLICATON, BY TYPE, 2022-2030 (USD MILLION)
TABLE 76 GERMANY: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 77 UK: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY SOURCE, 2022-2030 (USD MILLION)
TABLE 78 UK: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 79 UK: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
TABLE 80 UK: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC APPLICATION, BY TYPE, 2022-2030 (USD MILLION)
TABLE 81 UK: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR BIOCHEMICAL ANALYSIS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 82 UK: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR DIAGNOSTIC IMAGING, BY TYPE, 2022-2030 (USD MILLION)
TABLE 83 UK: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, FOR THERAPEUTIC APPLICATON, BY TYPE, 2022-2030 (USD MILLION)
TABLE 84 UK: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 85 FRANCE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY SOURCE, 2022-2030 (USD MILLION)
TABLE 86 FRANCE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 87 FRANCE: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
